Nitric oxide (NO) appears to be involved in virtually every aspect of cardiovascular biology. Most attention has been focused on the role of endothelial-derived NO in basal blood flow regulation by relaxing vascular smooth muscle; however, it is now known that NO derived from red blood cells (RBCs) plays a fundamental role in vascular homeostasis by enhancing oxygen (O 2 ) release at the cellular and physiological level. Hypoxia is an often seen problem in diverse conditions; systemic adaptations to hypoxia permit people to adjust to the hypoxic environment at high altitudes and to disease processes. In addition to the cardiopulmonary and hematologic adaptations that support systemic O 2 delivery in hypoxia, RBCs assist through newly described NO-based mechanisms, in line with their vital role in O 2 transport and delivery. Furthermore, to increase the local blood flow in proportion to metabolic demand, NO regulates membrane mechanical properties thereby modulating RBC deformability and O 2 carrying-releasing function. In this review article, we focus on the effect of NO bioactivity on RBC-based mechanisms that regulate blood flow and RBC deformability. RBC adaptations to hypoxia are summarized, with particular attention to NOdependent S-nitrosylation of membrane proteins and hemoglobin (S-nitrosohemoglobin). The NO/S-nitrosylation/RBC vasoregulatory cascade contributes fundamentally to the molecular understanding of the role of NO in human adaptation to hypoxia and may inform novel therapeutic strategies.
Introduction
Hypoxia is not only an often seen problem in plateau environment, but also caused by some physiology conditions such as ischemia, hemorrhage, stroke, premature birth, and exhaustive exercise. Hypoxia induces a mismatch between energy supply and demand which has the potential to cause cell death and organ failure. Studies have demonstrated that hypoxia increases the production of reactive oxygen (O 2 ) and nitrogen species, and limits the antioxidant capacity in red blood cell (RBC). In addition, membrane proteins crosslinking and extensive peroxidation of membrane lipids can occur, which can cause changes in fluidity, e.g. a fall in the membrane potential and an increase in the permeability to different ions, which finally leads to hemolysis [1, 2] . As a parallel increase in oxidative stress with hypoxia, good systemic and cellular responses would support global convective O 2 delivery for a progressive tolerance to hypoxia.
Systemic adaptation to hypoxia permits people successfully adjust to the hypoxic environment at high altitudes, even up to 5000 m, where O 2 pressure is about half of that at sea level. Usually, the adaptation to hypoxia is attributed to cardiopulmonary and hematologic responses that support systemic O 2 delivery [3] . Whenever arterial O 2 concentration is reduced, the hypoxic vasodilation will occur in order to increase blood flow in an attempt to restore O 2 supply. As a major signaling and effector molecule mediating the body's response to hypoxia, nitric oxide (NO) has a unique characteristic of vasodilation (improving blood flow and O 2 supply) and modulation of energetic metabolism (reducing O 2 consumption and promoting utilization of alternative pathways) [4, 5] . Among them, RBCs play an undoubted role in systemic adaptation to hypoxia, in line with their vital role in O 2 transport and delivery [6] [7] [8] [9] [10] [11] .
Cellular adaptations to hypoxia involve the homeostasis of NO [12, 13] , which involves the regulation of blood vessel tone to promote oxygenation and supply of tissues with glucose and other substances [10, 12, 14] . As a signal transduction molecule, NO plays an important role in the execution of the body's physiological functions. The primary investigated function is smooth muscle relaxation and stimulation of hypoxic dilatation [15, 16] , and it has other function to inhibit platelet activation, neurotransmission, and modulation of inflammation as well [17] [18] [19] . There are three nitric oxide synthases (NOS) isoforms responsible for the production of NO that have been identified: inducible NOS (iNOS), endothelial NOS (eNOS), and neuronal NOS (nNOS) [20] . There is evidence that RBCs from humans express an active and functional eNOS, which is localized in the plasma membrane and the cytoplasm of RBCs [21] . iNOS, in particular, is expressed in a wide variety of cell types, including cardiomyocytes and cardiac endothelial cells [22] , that can induce the release of fluxes of a higher order of magnitude of NO in response to some stimuli, such as hypoxia [23] or after stimulation with inflammatory mediators [22, 24] .
In vasculature, NO production is maintained by endothelial cells and RBCs. On other hand, it contributes to homeostasis by smooth muscle cells and RBC hemoglobin (Hb). In human blood, NO can be quickly oxidized to metastable intermediate nitrite (NO 2 − ) and finally oxidized to the stable metabolite nitrate (NO 3 − ) [25] . Nitrite has been shown to represent an endocrine bioavailable storage pool of NO that can be bioactivated under hypoxic conditions [26] [27] [28] [29] . RBC membrane induced conformational changes of the nitritereacted substance and facilitated the release of NO [30] , suggesting that nitrite stored in RBC itself can serve as a NO-equivalent donor during hypoxia. Due to the high-affinity binding properties to Hb, NO cannot operate, or even exist, as a free entity in the presence of excess heme/Hb [31] . Previous studies have shown that the interactions of NO with human Hb alternatively eliminate NO by converting it to NO 3 − , or tightly make a complex on the β subunit ferrous hemes, which can effectively quench NO bioactivity [31] . More recent work has raised the idea that NO groups can be efficiently transferred from the hemes to cysteine thiols within the β subunit (Cysβ93) to form bioactive nitrosothiols [32] , and then promote NO-dependent vasorelaxation or inhibition of platelet aggregation in the systemic circulation and even elicit any function in RBCs through reactions with thiols to form S-nitrosothiol (SNO) [33] .
As the main storage pool of NO and NO metabolism products, RBCs play an important role in transporting NO to the vasculature [34] . When RBCs pass through the microcirculation, they can sense tissue O 2 condition via their deoxygenation degree and couple this information to release NO, which enhances blood flow to hypoxic tissues [14, 35, 36] . On the contrary, NO is tightly linked to stabilizing the RBC structure and function. In recent years, more and more evidence strongly proved that NO takes part in modulating RBC function under various conditions, such as in sickle cell anemia (SCA) [37, 38] , RBC storage lesions [39, 40] , environment hypoxic [41, 42] , and RBC aging [43] . In fact, the key role of NO in regulating RBC function has been addressed [44] [45] [46] [47] [48] [49] [50] . These findings that NO and its SNO form affect blood flow and RBC functions provide a complete mechanism of its benefits in human adaptation to hypoxia, and introduce a number of potential therapies for ischemia and hypoxia disease.
In addition, a number of drugs with NO activity are crucial for the structural and functional abnormalities of RBC [39, 48, 51, 52] . NO (by inhaling NO or NO donor) can also improve the properties of stored RBC and effectively alleviate the damage caused by transfusing stored RBC [53] [54] [55] . Inhaled NO can be applied to various cardiovascular and respiratory diseases, but inhalation of high levels of NO appears to induce toxicity and side effects [56] . Sodium nitroprusside (SNP) is commonly used clinically as a treatment for severe cardiopulmonary diseases such as pulmonary hypertension. It is also an NO donor that can inhibit oxidative stress-induced impairment of RBC deformability in vitro [39] . Insulin, a drug clinically used to treat diabetes, has been shown to activate RBC-NOS by increasing its phosphorylation at Ser1177 [21] and plays a protective role in RBC deformability by increasing NO levels in vitro [57] . Acetylcholine (Ach) is also known to enhance NO production in endothelial cells [58] , and has the capability to increase the RBC deformability and O 2 carrying properties [48] , however the effect of Ach can be disturbed by fibrinogen [59] . These drugs have been clinically proved to be effective in treating cardiovascular diseases by enhancing the blood flow, but there is still a lack of clinical evidence to support that they cure hypoxic diseases by improving RBC function. A large number of animal experiments and clinical trials are needed to demonstrate their effectiveness in improving RBC structure and function of ischemia and hypoxia disease.
Although an excessive NO and accumulation of NO metabolites may damage the normal functions of cells, the roles of NO in maintaining RBC function and in human adaptation to hypoxia are confirmed. Several review articles have covered the modulation of blood flow and O 2 supply by NO in the cardiovascular system and in ischemic hypoxic conditions [4, 60, 61] , and the key roles of NO in human adaptation to hypoxia [12, 62] . However, maintaining the deformability and carrying-releasing O 2 capacity of RBC in hypoxia is also essential for human adaptation to hypoxia. There is no article reviewing the key role of NO in regulating RBC function to help RBC adaptation to hypoxia.
In this review article we highlight the crucial role of NO in maintaining RBC normal function during hypoxia through metabolic suppression and deformability maintenance, and also summarize various mechanisms through which NO reacts with protein thiol under hypoxia. We attempt to identify the position for NO in the RBCs adaptation to hypoxia. The NO/S-nitrosylation/RBC function cascade will contribute to the molecular understanding of a role of NO in RBC function, which helps human adaptation to hypoxia.
RBC Adaptation to Hypoxia
RBCs are the most abundant host cell in the human body that plays an undoubted role in human adaptation to hypoxia. For decades, great progress has made in understanding the response of RBCs to deoxygenation and hypoxia. Hypoxia induces systemic increase of erythropoietin (EPO) level [63] , which stimulates the production of mature RBCs from the bone marrow [64] . Increase in hematocrit (Hct), red cell volume (RCV), and total hemoglobin (THb) levels are observed after individual persons ascend to high altitudes, and the enhancements stabilize at relatively high levels, even though these adaptations are eventually lost following descent to low altitude [65, 66] .
In addition to physiological adaptation, RBCs respond to hypoxia also through the O 2 -dependent metabolic regulation, which involves the competitive binding of deoxyhemoglobin and glycolytic enzymes (GEs) to the N-terminal cytosolic domain of band 3 [10] . Over the years, structural and functional evidence has been obtained about the hypoxia-dependent promotion of the accumulation of 2,3-diphosphoglycerate (2,3-DPG), stabilization of the deoxygenated state of Hb, and cytosol acidification, which contribute to pH homeostasis and Hb-O 2 off-loading through the stabilization of the deoxygenated tense state (T) by negatively charged high phosphate compounds, such as adenosine triphosphate (ATP) and 2,3-DPG [6, 67 ]. An increase of ATP level was observed not only in lowlanders exposed to high altitude hypoxia at early stage [10] , but also in anaerobically stored RBC concentrates for transfusion purposes [68] [69] [70] . Recent studies have suggested that plasma adenosine and sphingosine-1-phosphate levels are positively correlated with initial altitude acclimatization and subsequent rapid acclimatization upon re-ascent [71, 72] . Exposure to hypoxia promotes the glycolytic fluxes in RBC, and also affects RBC's capacity to metabolize (consume or generate) carboxylic acids, as well as the purine salvage pathway which has potential benefits associated with hypoxic storage of packed RBCs [73, 74] .
Usually, hypoxia is supposed to limit the antioxidant potential of RBCs [75] and promote oxidative/reductive and nitrosative stress at high altitude [2] , however in early exposure to hypoxia, RBC metabolic adaptations to hypoxia in vivo result in glutathione (GSH) accumulation and oxidized glutathione (GSSG) depletion, consistent with reduced oxidative stress or increased de novo biosynthesis [10, 76] . Furthermore, RBCs can also be considered as an O 2 sensor. When RBCs pass through the microcirculation, they can sense tissue O 2 condition via their deoxygenation degree and couple this information to release NO, thereby enhancing blood flow to hypoxic tissues [14, 35, 36] . As the endocrine bioavailable storage pool of NO, nitrite can be bioactivated by Hb. Studies have demonstrated that the conversion of NO into SNO is essential to elicit its function in the systemic circulation [77, 78] . The genetic evidence strongly affirms the central role of SNO in NO biology and disease [79, 80] . At physiological concentrations of nitrite and deoxyHb, an S-nitrosothiol precursor is formed within seconds and SNO-Hb is produced at high yield upon its prompt exposure to O 2 or CO. Deoxygenation/reoxygenation cycling of oxyHb in the presence of physiological amounts of nitrite also efficiently produces SNO-Hb. In contrast, high amount of nitrite or delay in reoxygenation inhibits the production of SNO-Hb [81] . SNO-Hb [77] and RBCs containing SNO-Hb [78] exert NOdependent vasodilation to stimulate blood flow, especially under hypoxia. Pawloski et al. [82] suggested that membranes of RBCs account for the vasodilator activity of RBCs. Due to the presence of Cys within the N-terminus of band 3, it communicates with Cys within the membrane-spanning region of band 3, which in turn communicates with thiols in plasma. SNO-Hb introduces NO into the Cys of band 3 on the membrane of RBCs, and those membranes are then endowed with vasodilator activity. SNO-Hb within RBCs is in equilibrium with S-nitrosoglutathione (GSNO) in tissues [79] through SNO/thiol exchanges [83] . The vasodilation role of RBC is potentiated by GSH through the formation of GSNO [80] . In addition to vasodilation, SNO-Hb can also improve the O 2 delivery of RBC [84] . The SNO of RBC membrane protein also participates in regulating RBC deformability under various conditions [44] [45] [46] [47] [48] , which makes RBCs to successfully transport O 2 to hypoxic tissue.
The physiology changes mentioned above, especially the conversion of NO into SNO, help RBC maintain its deformability and capacity of carrying-releasing O 2 to transport and deliver O 2 , and also help human adaptation to hypoxia (Fig. 1) . However, such responses do not provide a full explanation of the acclimatization process, given that RBC function remains normal even though RBCs immerse in oxidative stress induced by hypoxia. In human blood, RBCs express a functional nitric oxide synthesis (RBC-NOS) [21] which is localized in the plasma membrane and the cytoplasm of RBCs [85] . Numerous studies have implied that NO is involved in the regulation of RBC hypoxia adaptation through various mechanisms.
NO and RBC Glycolysis Metabolism
As an integral part of the human physiological response to hypoxia, NO level is apparently increased upon exposure to hypoxia, which involves the regulation of blood vessel tone to promote oxygenation and supply tissues with glucose and other substances [10, 12, 14] .
The mature human RBC is non-nucleated and has no mitochondria required for efficient oxidative metabolism. When exposed to hypoxic conditions, RBCs are known to accelerate glucose consumption [10] . The glycolysis pathway is the only source of energy for mature RBCs which are modulated by the cytoplasmic domain of band 3 (cdb3) and O 2 -linked Hb transitions [86] [87] [88] [89] . Glyceraldehyde-3-phosphate dehydrogenase (GAPD), aldolase, phosphofructokinase, pyruvate kinase, and lactate dehydrogenase are assembled into a common GE complex bound to cdb3 [90, 91] . GAPD is an evolutionarily conserved enzyme that controls glucose flux through the canonical Embden-Meyerhof glycolytic pathway [92] . The GAPD which contributes to more than 60% of the total GE is the major GE bound to the membrane protein band 3 under physiological conditions [93] . The protection of GAPD activity depends on the redox status of amino acid residues, Cys149, 152, 247, and His179 in an oxidative stressdependent manner in the catalytic site. Storage-dependent reversible oxidation of GAPD represents a mechanistic adaptation in stored RBCs to promote glycolysis or the pentose phosphate pathway activation, and generate reducing equivalents [68] .
The bound-form is functionally inactive as a consequence of the interaction of its catalytic site with the N-terminal portion of the cytoplasmic domain of cdb3. This interaction does not affect GAPD activity [94] . It has been demonstrated that the GE-GAPD and cdb3 are the selective cell targets of NO [95, 96] , which are involved in this possible regulatory mechanism of glycolysis, and contain Cys residues which are crucial for their functions and susceptible to form reversible S-nitrosocysteines [97] [98] [99] . The covalent binding of NO to the cysteines (Cys149 and Cys247) in the catalytic site of GAPD promotes the dissociation of GAPD from cdb3 to form free Snitrosylated GAPD in RBC, whereas this modification reversibly inhibits the activity of GAPD [100, 101] . Although the effects of NO on the activity of glycolysis enzyme GAPD seem detrimental to the glycolysis pathway, the evidence of how rapid NO reversibly promotes the translocation of the GAPD from cdb3 into the cytosol had been produced. This process can increase glycolysis flux in the presence of low concentrations of NO donors [96, 102] . Many studies have shown that the reversible S-nitrosylation of the active site cysteine residue in GAPD represents a post-translational modification to protect protein function and stability, by preventing GAPD from further oxidative modification [100, [103] [104] [105] [106] [107] .
The nitrosylated glycolysis enzyme GAPD (SNO-GAPD) is temporarily inactivated because it can be converted into a free catalytically-active reduced form, depending on the intracellular redox condition, especially on GSH levels [108] . Therefore, maintaining the reducing activity of GSH appears to be necessary to maintain the proper reactivity of Cys residues involved in this NO-dependent regulation of glycolysis flux. Nevertheless, the reducing abilities of NADPH and GSH are limited when RBCs are exposed to hypoxia, which is closely linked to protein thiol oxidation challenge under hypoxic conditions [75] . The level of NO production which was induced by hypoxia is increased [4, 5] . It not only has the antioxidative effect on cysteine thiol but also works on the glutathione to form GSNO, prevents GSH from being oxidized to GSSG and maintains the reducibility of GSH. Of note, GSNO not only annihilates free radicals but also protects cell via its cGMPindependent nitrosylation actions [109] [110] [111] .
NO promotes the dissociation of RBC membrane-bound GE-GAPD to form free GAPD, and promotes the reductive effect of GSH, allowing the GE-GAPD to remain active, increasing glycolytic flux, and generating ATP to meet the increased energy demand under hypoxia. In addition, it can also influence the production of NADH and 2,3-DPG, two intermediates ultimately involved in the regulation of iron redox and O 2 affinity of Hb (Fig. 2) . The regulatory mechanisms through which NO affects glycolysis may in turn influence key aspects of the RBC function, such as cytoskeleton assembly, phosphorylation of proteins, and Hb binding and release of O 2 .
NO and RBC Deformability
The mature RBCs present double concave disc with excellent deformability, which is beneficial for deforming and squeezing to cross the narrow capillaries of the microcirculations much smaller than their diameter, thus delivering O 2 , CO 2 , and NO to tissues [112] . The maintenance of normal membrane deformability and mechanical stability is critical for human RBCs to undergo the normoxic and hypoxic cycling constantly exposed to oxidative stress during their 120-day life span [113] . Although RBCs have the physiological and metabolic adaptability to hypoxia (mentioned above), a constant exposure to oxidative stress during hypoxia can lead to changes in membrane lipid composition and state. In addition, it can alter the structure and function of membrane-bound proteins, which can impair the O 2 -transport properties of RBCs, and eventually trigger removal from circulation by the reticuloendothelial system [75, 114] . Mature RBCs do not have the nuclei to synthesize proteins for the replacement of damaged proteins, or the de novo synthesis of lipids that are responsible for their proper function and survival. Changes in the membrane lipids and any protein structure of cytoskeleton will influence the stability of membrane structure, and then impair the deformability of RBC.
NO plays an important signal transduction role in the execution of the body's physiological functions. Moreover, NO also protects against cellular damage and cytotoxicity from oxidative stress [103, 106] , and then regulates cellular functions in RBC deformability in various hypoxic diseases, such as SCA, septic shock storage, and acute phase of endotoxemia [37] [38] [39] [44] [45] [46] [47] [48] 50, 57] . The effect of NO donors on RBC deformability has been well established. It is suggested that RBCs from humans express active and functional eNOS, which are localized in the plasma membrane and the cytoplasm of RBCs [21] . RBC-NOS resemble a variety of specific
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RBC adaptation to hypoxia Figure 1 . The physiological changes of RBC adaptation to hypoxia Hypoxia can happen in various conditions, such as living in high altitude, anaerobic exercise, various anemia, blood storage, and ischemic shock. Hypoxia induces systemic increase of erythropoietin (EPO) levels, which stimulates the production of mature RBCs from the bone marrow. Increases in hematocrit (Hct), red cell volume (RCV), and total hemoglobin (THb) levels are observed. RBCs respond to hypoxia also through the oxygen-dependent metabolic regulation, which involves the accumulation of 2,3-diphosphoglycerate (2,3-DPG), stabilization the deoxygenated state of hemoglobin, and increased ATP levels and cytosol acidification, thereby contributes to pH homeostasis and hemoglobin oxygen off-loading. In addition, RBCs can also be considered as oxygen sensor, when RBCs pass through the microcirculation they can sense tissue oxygen conditions via their deoxygenation degree and couple this information to the release of nitric oxide (NO), which enhances blood flow to hypoxic tissue. In early exposure to hypoxia, RBC metabolic adaptations to hypoxia in vivo result in GSH accumulation and oxidized glutathione (GSSG) depletion, which is consistent with reduced oxidative stress or increased de novo biosynthesis. This helps RBC maintaining deformability and carrying-releasing oxygen capacity to transport and delivery oxygen, and then adapting to hypoxia.
regulatory pathways of eNOS that are regulated by the substrate L-arginine, by calcium, by phosphorylation or by mechanical stimulation via PI3 kinase [115, 116] . RBC-NOS activity regulates the electromechanical properties of RBC membrane [117] and this activation might be involved in the regulation of rheological properties of RBC [21] . The localization of RBC-NOS at the cytoplasm may increase methemoglobin (MetHb) concentration near the internal side of the membrane. Moreover, these mechanisms may alter the gradient of NO-related species across the RBC membrane and their diffusion chemistry, particularly in terms of the naturally formed Hb-spectrin conjugates at the RBC membrane [118] . Inhibition of NO formation by NOS inhibitor will drastically reduce the deformability of RBCs [21] . This deleterious effect suggests that the continuous formation of NO will determine membrane deformability. However, there is a debatable issue about the role of NO released from NOS on RBC deformability. Mozar et al. [38] suggested that RBC deformability of SCA can be modulated by RBC-NOS activity. Grau et al. [57, 119] revealed that activated RBC-NOS leads to increased NO production, S-nitrosylation of RBC proteins, and RBC deformability, whereas RBC-NOS inhibition results in opposite effects. However, the subsequent studies of the same group [40, 41, 120] suggested that high RBC-NOS activation is not associated with improved vascular function and RBC deformability in SCA and severe hypoxia, but RBC deformability improved by additional NO donors in mild hypoxia. From the studies summarized above, we infer that high oxidative stress in SCA and severe hypoxia may suppress plasma NO bioactivity and then impair the activity of regulating RBC deformability, but increasing the antioxidant capacity or NO levels by pharmacological treatment may improve vascular function and RBC rheology. RBC-NOS activation is associated with improved vascular function and RBC deformability in SCA and hypoxia, but high NOS activation may lead to accumulation of reactive nitrogen species (RNS) under oxidative stress, and ultimately reduces cell protection or even generates cytotoxic effects. It is possible that RBC-NOS-derived NO can be scavenged by oxyhemoglobin (HbO 2 ) under normoxic conditions and inactivated via conversion to MetHb and NO 3 − [121] , or it can react with ROS to form toxicity. RNS can lead to profound cellular disturbances [122] , which requires further study.
Considering that if there is a way to directly and accurately measure the physical properties of the RBC membrane, it may help us to understand the changes of RBC structure under the action of NO. The studies summarized above were carried out using the laserassisted optical rotational cell deformability analyzer, but the experimental methodology cannot reflect the change in RBC elasticity directly. In order to determine the single RBC deformability more accurately, optical tweezers were widely used to study the elasticity and deformability of RBC membranes with high accuracy and small damage to cells [123] [124] [125] . Recently, Liu et al. [126] proposed an optimized measurement method of RBC membrane shear modulus by incorporating acousto-optic deflector scanning optical tweezers system to measure RBC membrane elasticity. The optimized optical tweezers technique can directly and real-timely study single RBC membrane elasticity. In the research, they attempted to determine the correlation between the S-nitrosylation of blood and the deformability of RBCs at the micro level, and suggested that the S-nitrosylation of membrane protein spectrin is closely associated with maintaining RBC deformability.
The effect of NO on RBC deformability is well established, however, there is not much research on the mechanism of NO in A possible mechanism for the NO-dependent S-nitrosylation of GAPD thiols and the related effects on glycolysis A number of extracellular sources of NO, including activated phagocytes, platelets, endothelial cells, and drugs, can account for the exposure of RBC to relatively high concentrations of NO derivatives. Within the cell, the existence of NO is known to lead to the formation of protein and non-protein SNO. The Cys residues of GAPD and cdb3 can be potential targets of nitrosylation (or nitrosothiol-mediated transnitrosylation). This rapid and transient modification of critical Cys could affect the affinity between these two proteins, leading to GAPD translocation into the cytosol. Here, the free-form of the enzyme can be nitrosylated (transiently inactive) or reduced (catalytically-active). The equilibrium between these two forms depends on the intracellular redox and particularly on GSH levels. The NO-dependent translocation of GAPD into the cytosol can influence the glycolytic flux and thus can promote the production of ATP, NADH, and 2,3-DPG.
regulating RBC deformability. Marijke and his colleagues [57] first showed that RBC-NOS-produced NO plays an important role in improving RBC deformability through direct S-nitrosylation of cytoskeleton proteins, such as α-and β-spectrins. But subsequent studies of the same group revealed that enhanced RBC-NOS results in greater NO production and S-nitrosylation of α-and β-spectrins accompanied by the blunted RBC deformability and microvascular reactivity [57, 120] . Therefore, we think that the S-nitrosylation of α-and β-spectrins has yet to be explored for the understanding of the regulatory mechanism of NO in RBC deformability. Belanger et al. [37] suggested that NO released from NO donor (SNP) may be able to protect RBC deformability by inhibiting the Gardos channel in sickle cell disease (SCD). Barodka et al. [39] , dehydration and shrinkage of RBC, thereby increasing RBC stiffness and decreasing RBC deformability [128] . Moreover, increase of intracellular Ca 2+ induces band 3 tyrosine phosphorylation, involving an apparent protein tyrosine phosphatase (PTP) inhibition via dissociation from band 3 [129] . Inhibition of PTP has been shown to be responsible for other cases of oxidative stressinduced tyrosine phosphorylation [130] . But the exact mechanism by which NO regulates RBC deformability is not clear yet.
To discuss the reasonable mechanisms through which NO modulates RBC deformability, we focused on the cytoskeleton and the membrane protein of RBCs which can react with NO and its derivates, thus affecting the skeletal protein structure and stability and improving the deformability of RBCs to maintain blood flow and ameliorate hypoxic-ischemic conditions. The relationship between the maintaining of RBC deformability and NO is indicated by the correlation between the reversible reaction of NO and protein cysteine residues. NO binds to the free thiol groups of RBC proteins that are the selective modification of protein cysteine residues to form S-nitrosocysteine, which represents a post-translational modification to regulate protein function, stability and location [106] , as well as to protect the target cysteine residue(s) from oxidative damage [103] [104] [105] .
RBC deformability is determined by properties of the RBC membrane lipids, integral proteins and underlying cytoskeletal network which is connected with the spanning membrane proteins [113, 131, 132] . As the major RBC membrane-spanning protein in the lipid bilayer, band 3 plays an important role in the unique distribution pattern of RBC [133, 134] , which is responsible for RBC mechanical deformations which occur during the passage of RBCs through small capillaries. The function of band 3 is mainly regulated by its phosphorylation status [135] [136] [137] (Fig. 3A) . Its phosphorylation modification leads to the dissociation of ankyrin from band 3 [138] , which influences the interaction between the anchor and spectrin, breaks the cytoskeleton network structure, and weakens the membrane structure stability.
Early studies by Azarov et al. [139] and Huang et al. [140] suggested that the binding of deoxygenated Hb at the band 3 protein in submembrane cytoskeleton increased the membrane permeability for NO by ∼10 folds than that under oxygenated conditions, thereby allowing more NO under deoxygenated conditions and less NO under oxygenated conditions passing through the RBC membrane for NO-RBC interactions. It is suggested that thiol-reactive substances bound to the Hb-Cysβ93 can be transported in a thioldependent manner by band 3 on the basis of the intrinsic interaction between the two proteins, which subsequently mediates the membrane transport of the substances from the RBCs to the plasma [141] . Thus, band 3 plays a key role in the diffusion of NO in both directions of the RBC plasma membrane depending on the tissue O 2 partial pressure. In addition, NO can also influence band 3 tyrosine phosphorylation, ultimately affecting the affinity between the anchor and N-terminal cdb3 protein [138, 142] . Tyrosine phosphorylation of band 3 is induced by several physiologic stimuli, including malaria parasite invasion, cell shrinkage, normal cell aging, and oxidant stress [138] . Band 3 phosphorylation is promoted by protein tyrosine kinases (PTKs) and dephosphorylation is catalyzed by PTPs [143, 144] . PTPs are associated with band 3 in the human RBC membrane, which is normally highly active and prevents the accumulation of band 3 phosphotyrosine [129] . When PTPs dissociate from band 3, the cysteine residue of PTPs is essential for catalysis and susceptible to oxidation [145] . The ROS that are produced in hypoxia, usually H 2 O 2 , inhibit the PTPs by oxidizing the catalytic cysteine, which enables the complete phosphorylation of band 3 tyrosine residue by the PTKs [146] . RBC membrane band 3 tyrosine phosphorylation results in a modest degree of dissociation of ankyrin from the cdb3 [138] , which makes the immobile band 3 turning into mobile band 3. This dissociation process may be accelerated by the peroxidation of the RBC membrane and high-affinity cooperative binding of metHb to the cytoplasmic domain of mobile band 3 [147] . As metHb is a tetramer, it can form a bridge between a number of diffusing band 3 dimers to irreversible phosphorylation and clustering, and then results in impaired RBC deformability (Fig. 3B ).
An increased concentration of NO was found in hypoxia induced by NOS and from the reduction of NO 2 − by Fe 2+ Hb [16, 30] . The cdb3 and membrane thiol residual are also the selective cell targets of NO [96] . The increased NO in hypoxia protects the function of the protein by reacting with protein reactive cysteine thiols [97] [98] [99] , which is a reversible post-translational protein modification involved in redox process, and also prevents the target cysteine residue(s) from the further oxidative modification [106] . The modification of PTP thiol by NO may represent a regulatory mechanism of band 3 phosphorylation, while dephosphorylation of band 3 by PTPs can reduce the dissociation of band 3 from the spectrinactin skeleton and thus inhibit the immobile band 3 from turning into mobile band 3 [138] which has a high-affinity with metHb, forms irreversible bonds, and then induces band 3 clustering [147] [148] [149] , thereby triggering a cascade of events finally leading to hemolysis (Fig. 3C) . At the same time, NO can bind with the highly conserved β-globin chain Cys93 of deoxygenated Hb to form bioactive S-nitrosohemoglobin (SNO-Hb) that acts as a carrier of NO bioactivity [62, 82] and decreases metHb bound to membrane protein band 3. These combined effects of NO in RBC membrane protein and Hb improve the RBC deformability. Therefore NO can reduce band 3 tyrosine phosphorylation under hypoxia-induced oxidative stress and decrease metHb binding to membrane protein band 3, thereby enhancing RBC deformability to prevent RBCs from hypoxia-induced hemorheological abnormalities. RBCs are the major intravascular storage site of nitrite in human blood [34] . Several studies have proposed that nitrite accumulation accompanied with RNS [122] can induce the formation of 3-nitrotyrosine in RBC membrane proteins. Several investigations suggested that tyrosine nitration may be involved directly or indirectly in the regulation of signaling proteins, or at least may cooperate with tyrosine phosphorylation [150] to impair RBC deformability. However, several mammalian enzymes in the human body, such as xanthine oxidase, cytochrome C oxidase, and even endothelial NO synthase, have been found to reduce nitrite under hypoxia, even though the normoxic functions of these enzymes are very different [151] [152] [153] [154] . The deoxygenated states of Hb and myoglobin have been characterized as allosterically regulated nitrite reductases [28] . Under conditions of hypoxia and ischemia, nitrite is converted into SNO by deoxyhemoglobin and deoxymyoglobin [155] [156] [157] . It has been revealed that as O 2 levels fall deeper and deeper from physiological hypoxia within the blood vessels and tissue to pathological hypoxia in the setting of ischemia-reperfusion injury, additional reduction mechanisms are being successively activated to provide a graded generation of NO to execute vasodilation function or others [158] . Therefore, the various mechanisms may operate in a cooperative fashion to decrease the formation of 3-nitrotyrosine and subsequently to decrease the nitration damage.
NO and RBCs Carrying-Releasing Oxygen
A progressive tolerance to hypoxia is traditionally ascribed to cardiopulmonary and hematological responses that support global convective O 2 delivery. NO participates in this process by increasing local blood flow and O 2 delivery to help systemic O 2 homeostasis. However, it is not always clear whether an increased or decreased Hb-O 2 affinity should be expected to improve tissue O 2 delivery under hypoxia, which is attributed to Hb carrying-releasing O 2 capacity. In this review, we propose that NO may also regulate the complex process of Hb carrying and releasing O 2 (Fig. 4) .
Hb has two different conformations, R-state (relaxed state, high O 2 affinity) and T-state (tense state, efficiently release O 2 ). Hb carrying-releasing O 2 is determined by a variety of metabolites in the intracellular compartment, such as protons (H A potential mechanism for the effect of NO-dependent S-nitrosylation on membrane protein band 3 phosphorylation and metHb (A) The band 3 tetramer formed by two dimers and linked to the skeletal network through interaction with ankyrin is immobile and is thus uniformly distributed in the membrane. The mobile band 3 dimer is not connected to the skeleton protein, and it is easy to react with NO to form SNO. The protein tyrosine-phosphatases (PTPs) are associated with band 3 in the human RBC membrane, which is normally highly active and prevents the accumulation of band 3 phosphotyrosine. (B) Hypoxia-induced RBC membrane protein band 3 tyrosine phosphorylation and membrane lipid peroxidation involve an apparent PTP inhibition via dissociation from band 3 and oxidization by ROS. RBC membrane band 3 tyrosine phosphorylation results in a modest degree of dissociation of ankyrin from the cytoplasmic domain of band 3, making the immobile band 3 turns into mobile band 3. The peroxidation of the RBC membrane lipid probably accelerates this dissociation process. These two mechanisms induce metHb binding to the cytoplasmic domain of mobile band 3 with high-affinity. As metHb is a tetramer, it can form a bridge between a number of diffusing band 3 dimers for irreversible phosphorylation and clustering, which results in impaired RBC deformability. (C) An increase of NO production was found in hypoxia-induced iNOS and in the reduction of NO 2 − by Fe 2+ Hb. The increased NO in hypoxia protects the dephosphorylation activity of PTP by reacting with reactive cysteine thiols, thereby prevents the target cysteine residue(s) from further oxidative modification and inhibits the dissociation of ankyrin from band 3 by reducing the phosphorylation of band 3 tyrosine. The band 3 (cdb3) and membrane thiol residuals are also the specific cell targets of NO, and the formation of S-nitrosocysteines prevents band 3 and membrane from oxidative damage resulted from hypoxia stress. NO can bind to the highly conserved β-globin chain cysteine 93 residue of deoxygenated Hb to form bioactive S-nitrosohemoglobin (SNO-Hb) which acts as a carrier of NO and decreases metHb binding to membrane protein band 3. The combined effect of NO in RBC membrane protein and Hb improves RBC deformability.
demonstrated that hypoxia promotes the accumulation of 2,3-DPG, a compound that decreases the Hb affinity for O 2 , while stabilizes the deoxygenated state of Hb and cytosol acidification. Therefore, the accumulation of 2,3-DPG also contributes to pH homeostasis and HbO 2 off-loading [6] . When glucose metabolism and Hb binding to band 3 occur, O 2 will be released to hypoxic tissue. This process has been reported to be NO-dependent in RBCs, as the cytoplasmic domain of cdb3 constitutes the only binding site recognized by deoxyHb, but not oxyHb. Since the Hb-cdb3 interaction is strongly O 2 -dependent, these findings may suggest that band 3 regulates the RBC Hb carrying-releasing O 2 properties through its reversible oxygenationdependent association with deoxyHb [87, 88, 159] . The normal structure and function of band 3 are important for O 2 carryingreleasing in RBCs, which is regulated by NO. As the most abundant RBC membrane protein, band 3 modulates CO 2 transport in RBCs through a mechanism called 'chloride shift' (HCO 3
Therefore, this mechanism contributes to pH homeostasis and O 2 off-loading by promoting the 'Bohr effect'. As a result of membrane modulation of HbO 2 affinity, Hb at the membrane inner surface in contact with the N-terminal region of band 3 can preferentially bind with O 2 at low O 2 tension and then releases it upon saturation with 2,3-DPG in the interior of RBC, suggesting that band 3 influences the cooperation of O 2 with Hb, and possibility affects Hb in transporting O 2 [160] . NO exhibits high affinity with the hemoproteins, particularly with Hb [161] . The affinity of Hb for NO is similar to that for O 2 , that is, high in the relaxed deoxygenated state and low in the tense oxygenated state [78] . NO can bind to the highly conserved β-globin chain Cysβ93 of deoxygenated Hb to form bioactive S-nitrosohemoglobin (SNO-Hb) which acts as a carrier of NO [62, 82] . Stamler et al. [77, 78] suggested that the allosteric transition in Hb (from R to T) controls the reactivity of two highly conserved cysteines (Cysβ93) that can react with NO or SNO. SNO-Hb reversibly binds to the membrane primarily through the interaction with band 3 via its N-terminal cytoplasmic domain (cdb3) [159] . The O 2 -dependent regulation of RBC properties might be mediated by the reversible association of deoxyHb with band 3 [87, 159] . Furthermore, the availability of the Cysβ93 thiol depends on the quaternary conformation with greater accessibility in the oxygenated R-state than in the deoxygenated T-state. Thiol affinity for (S) NO is high in the R-state but low in the T-state. SNO-Hb in T-state will shift the coupled equilibrium between SNO in RBCs toward SNO in tissues. The genetic evidence confirmed that Cysβ93-derived SNO bioactivity is essential for tissue oxygenation by RBCs within the respiratory cycle, which is required for both normal cardiovascular function and circulatory adaptation to hypoxia [80] . In other words, the NO group is released from thiols of Hb under low PO 2 [78] . Therefore, Stamler et al. [78] proposed that partial deoxygenation of SNO-Hb in these vessels might actually promote O 2 delivery by liberating (S)NO. When Hb is oxygenated and the conformation is shifted from T-state to R-state, this SNO-Cysβ93 is exposed and allows NO release from Hb Cysβ93 onto a cysteine thiol within cdb3, which favors generation and release of a significant portion of RBC vasodilator activity, such as the release of SNO [78, 82, 162] . This rapid and transient modification of critical Cys within cdb3 can affect the affinity between band 3 and GAPD, allowing the GE-GAPD translocation from the cytosolic domain of the membrane protein band 3 into the cytosol, and then making the enzyme release from the bound-form to free-form [142, 163] . The free-form GAPD can be nitrosylated by NO into a transiently inactive form which can also be reduced by GSH back into a catalytically-active form. This regulatory mechanism influences the glycolytic flux and thus promotes the accumulation of NADH and 2,3-DPG, two intermediates that regulate the iron redox and stabilize the deoxygenated T-state of Hb, triggering O 2 off-loading through the Bohr effect [96, 102] . It has been suggested that NO release from Hb Cysβ93 is coordinated with O 2 release, which is essential for both normal cardiovascular function and circulatory adaptation to hypoxia [77, 80] Improving RBC deformability. The increased NO in hypoxia protects the function of protein tyrosine phosphorylase (PTP) by NO-dependent S-nitrosylation, while the dephosphorylation of band.3 tyrosine by SNO-PTP can reduce the dissociation of band 3 from the spectrin-actin skeleton which has a high-affinity for metHb and forms irreversible bonds and then induces band 3 clustering. The S-nitrosylation of membrane protein band 3/spectrin or others can protect those proteins under oxidative stress, thus maintaining the stability of membrane structure. Meanwhile, the increase of metHb reductase NADH and SNO-Hb may decrease metHb binding to membrane protein band 3, which influences RBC cytoskeleton assembly. Therefore, NO-dependent S-nitrosylation reduces band 3 tyrosine phosphorylation under hypoxia-induced oxidative stress and decreases metHb binding to membrane protein band 3, thereby enhancing RBC deformability to prevent RBCs from hypoxia-induced hemorheological abnormalities. The S-nitrosylation of glutathione (GSNO) is in equilibrium with SNO-proteins in RBC, which prevents the accumulation of SNO.
carrying-releasing O 2 by adjusting RBC glycolysis metabolism and the equilibrium between Fe(II) and metHb; (2) regulating RBC deformability by NO-dependent S-nitrosylation of the membrane and membrane-bound proteins. The two pathways exist side by side and play a part together, and none is dispensable, in the process of NO regulation of RBC function for adaptation to hypoxia. The role of NO in Hb allosteric transition and its effect on Hb carryingreleasing O 2 in hypoxia are not very convincing. Although the release of (S)NO from Hb is closely associated with the allosteric transition in Hb, this is a very complicated process. Many key questions related to Hb nitrosylation and its control need to be answered in the future. Another very important aspect that needs more attention in NO regulation of Hb carrying-releasing O 2 is the role of membrane protein band 3 in Hb allosteric transition and the accompanied carrying-releasing of NO and O 2 to vasculature. Understanding the exact role of NO in the process of RBC adaptation to hypoxia will provide a more comprehensive explanation of human adaptation to hypoxia, which may help to develop new therapeutic approaches for ischemic and hypoxic conditions, such as SCA, in patients.
